Recruiting PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT05434234

A Study of YL201 in Patients With Advanced Solid Tumors

A Phase 1A/1B, Multicenter, Nonrandomized, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL201 as a Single Agent and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors

Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.

Conditions Advanced Solid Tumor

Interventions YL201 YL201 and atezolizumab

Updated 15 times since 2022 Last updated: Nov 7, 2025 Started: May 25, 2022 Primary completion: Apr 6, 2027 Completion: Oct 6, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Advanced Solid Tumor, this trial is actively recruiting participants. The trial is conducted by MediLink Therapeutics (Suzhou) Co., Ltd. and has accumulated 15 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

15 versions recorded

Dec 2025 — Present [monthly]

Recruiting PHASE1/PHASE2
Nov 2025 — Dec 2025 [monthly]

Recruiting PHASE1/PHASE2
Oct 2025 — Nov 2025 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1 → PHASE1/PHASE2
Sep 2025 — Oct 2025 [monthly]

Recruiting PHASE1
Apr 2025 — Sep 2025 [monthly]

Recruiting PHASE1

▶ Show 10 earlier versions

Mar 2025 — Apr 2025 [monthly]

Recruiting PHASE1
Jan 2025 — Mar 2025 [monthly]

Recruiting PHASE1
Dec 2024 — Jan 2025 [monthly]

Recruiting PHASE1
Sep 2024 — Dec 2024 [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1
Jun 2023 — Jul 2024 [monthly]

Recruiting PHASE1
Mar 2023 — Jun 2023 [monthly]

Recruiting PHASE1
Dec 2022 — Mar 2023 [monthly]

Recruiting PHASE1
Sep 2022 — Dec 2022 [monthly]

Recruiting PHASE1
Jul 2022 — Sep 2022 [monthly]

Recruiting PHASE1

First recorded

May 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

MediLink Therapeutics (Suzhou) Co., Ltd.

Data source: MediLink Therapeutics (Suzhou) Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Barcelona, Spain , Bordeaux, France , Boston, United States , Brampton, Canada , Chapel Hill, United States , Detroit, United States , Dijon, France , Edmonton, Canada , Fair Oaks, United States and 33 more locations